PE20011095A1 - Composicion que coprende un factor de crecimiento y un inhibidor de proteasas utiles para el tratamiento de tejidos danados - Google Patents

Composicion que coprende un factor de crecimiento y un inhibidor de proteasas utiles para el tratamiento de tejidos danados

Info

Publication number
PE20011095A1
PE20011095A1 PE2000001405A PE0014052000A PE20011095A1 PE 20011095 A1 PE20011095 A1 PE 20011095A1 PE 2000001405 A PE2000001405 A PE 2000001405A PE 0014052000 A PE0014052000 A PE 0014052000A PE 20011095 A1 PE20011095 A1 PE 20011095A1
Authority
PE
Peru
Prior art keywords
growth factor
inhibitor
factor
composition
treatment
Prior art date
Application number
PE2000001405A
Other languages
English (en)
Inventor
Michael John Davies
Nicholas Laurence Occleston
Fraser Stuart Mcintosh
Jonathan Paul Huggins
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20011095A1 publication Critical patent/PE20011095A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

SE REFIERE A UNA COMPOSICION QUE COMPRENDE a)FACTOR DE CRECIMIENTO COMO CHRYSALIN, FACTOR DE CRECIMIENTO DEL ENDOTELIO VASCULAR (VEGF), FACTOR DE CRECIMIENTO EPIDERMICO (EGF), FACTOR DE CRECIMIENTO DERIVADO DE PLAQUETAS (PDGF), FACTOR DE CRECIMIENTO DE FIBROBLASTOS (FGF), FACTOR DE CRECIMIENTO DERIVADO DE TEJIDO CONJUNTIVO (CTGF), FACTOR DE CRECIMIENTO DERIVADO DE QUERATOCITOS (KGF), FACTOR DE CRECIMIENTO DE TRANSFORMACION (TGF), FACTOR ESTIMULADOR DE COLONIAS (CSF), b)AGENTE INHIBIDOR DE PROTEASA, INHIBIDOR DEL ACTIVADOR DE PLASMINOGENO TIPO UROQUINASA, INHIBIDOR DE METALOPROTEASA; c)VEHICULO, DILUYENTE. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. LA COMPOSICION SE CARACTERIZA PORQUE EL INHIBIDOR DE PROTEASAS ESPECIFICAS ES REGULADA POSITIVAMENTE EN UNA HERIDA O LA COMBINACION DEL INHIBIDOR Y EL FACTOR PRODUCE UN EFECTO SINERGICO. LA COMPOSICION PUEDE SER UTIL PARA EL TRATAMIENTO DE TEJIDO DANADO, HERIDA CRONICA, ULCERA DERMICA
PE2000001405A 1999-12-29 2000-12-27 Composicion que coprende un factor de crecimiento y un inhibidor de proteasas utiles para el tratamiento de tejidos danados PE20011095A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9930768.8A GB9930768D0 (en) 1999-12-29 1999-12-29 Composition

Publications (1)

Publication Number Publication Date
PE20011095A1 true PE20011095A1 (es) 2001-10-27

Family

ID=10867127

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000001405A PE20011095A1 (es) 1999-12-29 2000-12-27 Composicion que coprende un factor de crecimiento y un inhibidor de proteasas utiles para el tratamiento de tejidos danados

Country Status (12)

Country Link
EP (1) EP1242120A2 (es)
JP (1) JP2003519193A (es)
AR (1) AR027122A1 (es)
AU (1) AU1878201A (es)
CA (1) CA2395487A1 (es)
CO (1) CO5271671A1 (es)
EC (1) ECSP003859A (es)
GB (1) GB9930768D0 (es)
GT (1) GT200000224A (es)
PE (1) PE20011095A1 (es)
UY (1) UY26514A1 (es)
WO (1) WO2001049309A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
ES2304401T3 (es) 2000-10-16 2008-10-16 Genentech, Inc. Metodos de tratamiento que utilizan polipeptidos wisp.
DK1414487T3 (da) 2001-07-27 2006-10-09 Orthologic Corp Anvendelse af thrombin-peptidderivater til behandling af kroniske hudsår
WO2003029819A1 (fr) * 2001-09-28 2003-04-10 Takeda Chemical Industries, Ltd. Procede pour le criblage preventif / le traitement des maladies d'os ou d'articulations
JP2006514822A (ja) 2002-07-02 2006-05-18 ザ ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム トロンビンペプチド誘導体
ATE357928T1 (de) 2003-12-31 2007-04-15 Orthologic Corp Pharmazeutische zusammensetzung für thrombinpeptidderivaten
ES2370040T3 (es) 2005-10-07 2011-12-12 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L. Vacuna de metaloproteinasa 11 de la matriz.
CN101965193A (zh) * 2006-11-15 2011-02-02 科达治疗公司 用于伤口愈合的改进方法和组合物
KR101629504B1 (ko) * 2014-04-14 2016-06-10 주식회사 엘지생활건강 사이토카인 조합을 함유하는 피부 상태 개선용 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01279840A (ja) * 1988-04-28 1989-11-10 Wakunaga Pharmaceut Co Ltd 新規外用組成物
GB9405076D0 (en) * 1994-03-16 1994-04-27 Inst Of Ophtalmology A medical use of matrix metalloproteinase inhibitors

Also Published As

Publication number Publication date
CA2395487A1 (en) 2001-07-12
AU1878201A (en) 2001-07-16
GT200000224A (es) 2002-06-15
ECSP003859A (es) 2002-09-27
EP1242120A2 (en) 2002-09-25
GB9930768D0 (en) 2000-02-16
UY26514A1 (es) 2001-07-31
JP2003519193A (ja) 2003-06-17
WO2001049309A2 (en) 2001-07-12
AR027122A1 (es) 2003-03-12
WO2001049309A3 (en) 2002-02-28
CO5271671A1 (es) 2003-04-30

Similar Documents

Publication Publication Date Title
Strecker-McGraw et al. Soft tissue wounds and principles of healing
Morton et al. Wound healing update
Eldad et al. Early nonsurgical removal of chemically injured tissue enhances wound healing in partial thickness burns
PE20011095A1 (es) Composicion que coprende un factor de crecimiento y un inhibidor de proteasas utiles para el tratamiento de tejidos danados
AR024813A1 (es) Tratamiento y composicion para lograr beneficios anti-envejecimiento de la piel por activacion de proteasa del estrato corneo.
HK1136480A1 (en) Solid dressing for treating wounded tissue
DE69429450D1 (de) Die verwendung von angiotensin iii und seiner analoge für die gewebeheilung
DE60036490D1 (de) Zusammensetzung zur behandlung von prostatakrebs
HK1070290A1 (en) Growth factor complex
Menke et al. Biologic therapeutics and molecular profiling to optimize wound healing
HK1116683A1 (en) New pharmaceutical compositions containing hyaluronic acid or its derivatives and collagenase for the topical treatment of wounds, burns and ulcers
Verbelen et al. Exposed tibial bone after burns: flap reconstruction versus dermal substitute
Clark Fibrin glue for wound repair: facts and fancy
Donegan et al. An overview of factors maximizing successful split-thickness skin grafting in diabetic wounds
DE69902234D1 (de) Matrixprotein enthaltende zusammensetzungen zur wundheilung
BR0313370A (pt) composição despigmentante para a pele, uso de uma composição despigmentante para a pele, uso cosmético da mesma e método para um tratamento cosmético não terapêutico para embelezar a pele
AR020455A1 (es) Composicion insecticida
ATE499944T1 (de) Verwendung von einem extrakt von einem nicht- photosynthetischen faserigen bakterium zur beförderung der herstellung von superoxid- dismutase
Xiao et al. A new method of microskin autografting with a Vaseline-based moisture dressing on granulation tissue
DE50214346D1 (de) Verwendung von zwei-komponenten zusammensetzungen inozyten umfassenden zelltransplantaten
AU5416994A (en) Composition for controlling dermatomycoses and their agents, as well as transpiration and bodily odours
WO2005077402A1 (en) Honey based gel formulations
MX2022000877A (es) Nueva composicion antioxidante para cicatrizacion de heridas.
Cryptococcus CHAPTER SUMMARY
NARAYANASHARMA Role of nitric oxide in wound healing: Facilitatory effects of nitrosoglutathione-A nitric oxide donor on the extracellular matrix deposition characteristics of wound healing

Legal Events

Date Code Title Description
FA Abandonment or withdrawal